The recent European Commission’s (EC) approval of Eli Lilly’s (NYSE: LLY) Mounjaro (tirzepatide) for treating type 2 diabetes (T2D) is of paramount interest, and not only for T2D patients, as it could address vital unmet needs for other GIP/GLP-1 receptor agonist–treat Published diseases, including obesity.
The drug has the potential to address a key unmet need by introducing a new mechanism of action into the T2D space - which is expected to reach $91.6 billion by 2029 as projected by data and analytics company GlobalData in 2021 - and potentially the obesity space.
Mounjaro is a glucagon like peptide 1 (GLP-1) receptor agonist, similar to many other treatments for T2D and obesity on the market, including Novo Nordisk’s (NOV: N) Wegovy (semaglutide), the first GLP-1 agonist approved for weight loss, and the firm’s Saxenda (liraglutide).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze